Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Proximal DVT · Hospitalised patients1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.26 [0.13, 0.53] | 8 studies · 1035 participants | Moderate |
Intervention NR Pulmonary embolism · Hospitalised patients1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.38 [0.15, 0.96] | 5 studies · 569 participants | Low |
Intervention NR Adverse effects and complications · Hospitalised patients1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Deep vein thrombosis (DVT) · Patients hospitalised for surgical procedures1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.35 [0.28, 0.44] | 19 studies · 2693 participants | High |
Intervention NR Proximal DVT · Patients hospitalised for surgical procedures1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.26 [0.13, 0.53] | 7 studies · 875 participants | Moderate |
Intervention NR Pulmonary embolism · Patients hospitalised for surgical procedures1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.38 [0.15, 0.96] | 5 studies · 569 participants | Low |
Intervention NR Adverse effects and complications · Patients hospitalised for surgical procedures1 Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Deep vein thrombosis (DVT) · Patients hospitalised following acute myocardial infarction Graduated compression stockings for prevention of deep vein thrombosis (2018) · Cochrane | OR 0.12 [0.03, 0.51] | NR | Low |
Autologous vein vs other graft types Primary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 0.59 [0.37, 0.94] | NR | Low |
Externally supported graft vs unsupported graft Primary patency (60 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Externally supported graft vs unsupported graft Secondary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 2.25 [1.24, 4.07] | NR | Low |
Externally supported graft vs unsupported graft Limb salvage · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
PTFE vs PTFE with vein cuff Primary patency (24 months) · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.08 [0.58, 2.01] | NR | Very low |
PTFE vs PTFE with vein cuff Primary patency (60 months) · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
PTFE vs PTFE with vein cuff Secondary patency (24 months) · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.22 [0.67, 2.23] | NR | Very low |
PTFE vs PTFE with vein cuff Limb salvage (24 months) · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.34 [0.72, 2.49] | NR | Low |
Autologous vein vs other graft types Primary patency (60 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 0.47 [0.28, 0.8] | NR | Moderate |
Autologous vein vs other graft types Secondary patency (60 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 0.41 [0.22, 0.74] | NR | Low |
Autologous vein vs other graft types Limb salvage · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
PTFE vs Dacron Primary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.23 [0.92, 1.65] | NR | Low |
PTFE vs Dacron Primary patency (60 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.67 [0.96, 2.9] | NR | Low |
PTFE vs Dacron Secondary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 1.54 [1.04, 2.28] | NR | Low |
PTFE vs Dacron Limb salvage (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 0.82 [0.27, 2.48] | NR | Low |
Externally supported graft vs unsupported graft Primary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery Graft type for femoro‐popliteal bypass surgery (2018) · Cochrane | OR 2.08 [1.29, 3.35] | NR | Low |
Intervention NR Limb salvage at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 1.02 [0.41, 2.55] | 4 studies · 636 participants | Low |
Intervention NR Amputation at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 0.97 [0.51, 1.85] | 3 studies · 616 participants | Low |
Intervention NR Death at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 0.59 [0.31, 1.14] | 4 studies · 636 participants | Moderate |
Intervention NR Vessel patency at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 0.46 [0.08, 2.76] | 1 study · 20 participants | Very low |
Intervention NR Major haemorrhage at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 3.22 [1.79, 5.78] | 4 studies · 1070 participants | Low |
Intervention NR Stroke at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 5.33 [0.95, 30.11] | 5 studies · 1180 participants | Low |
Intervention NR Distal embolisation at 30 days · patients seeking treatment for initial management of acute limb ischaemia Surgery versus thrombolysis for initial management of acute limb ischaemia (2018) · Cochrane | OR 31.68 [6.23, 161.07] | 3 studies · 678 participants | Very low |
Treatment of DVT at home vs treatment Recurrence of VTE · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | RR 0.58 [0.39, 0.86] | 6 studies · 1708 participants | Low |
Treatment of DVT at home vs treatment Venous gangrene · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | no estimate extracted | NR | No studies |
Treatment of DVT at home vs treatment Major bleeding · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | RR 0.67 [0.33, 1.36] | 6 studies · 1708 participants | Low |
Treatment of DVT at home vs treatment Minor bleeding · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | RR 1.29 [0.94, 1.78] | 6 studies · 1708 participants | Low |
Treatment of DVT at home vs treatment Death f · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | RR 0.69 [0.44, 1.09] | 6 studies · 1708 participants | Low |
Treatment of DVT at home vs treatment Patient satisfaction/Quality of life · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | no estimate extracted | 3 studies · 1031 participants | Very low |
Treatment of DVT at home vs treatment Cost‐effectivenessf · people with diagnosed DVT Home versus in‐patient treatment for deep vein thrombosis (2018) · Cochrane | no estimate extracted | 4 studies · 834 participants | Very low |
Fondaparinux vs placebo Symptomatic VTE Ventilation‐perfusion scanning, helical computed tomography, pulmonary angiography, autopsy, ultrasonography, or venography · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.15 [0.04, 0.5] | 1 study · 3002 participants | Moderate |
Prophylactic LMWH vs placebo Extension or recurrence (or both) of ST · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.44 [0.26, 0.74] | 1 study · 222 participants | Low |
Prophylactic LMWH vs placebo Mortality · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic LMWH vs placebo Minor bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic LMWH vs placebo Adverse effects of treatment · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Therapeutic LMWH vs placebo Symptomatic VTE · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.85 [0.23, 3.06] | 1 study · 218 participants | Low |
Therapeutic LMWH vs placebo Major bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | 1 study · 218 participants | Low |
Therapeutic LMWH vs placebo Extension or recurrence (or both) of ST · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.46 [0.27, 0.77] | 1 study · 218 participants | Low |
Therapeutic LMWH vs placebo Mortality · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Therapeutic LMWH vs placebo Minor bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Therapeutic LMWH vs placebo Adverse effects of treatment · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs placebo Major bleeding · people with ST of the leg Treatment for superficial thrombophlebitis of the leg (2018) · Cochrane | RR 0.99 [0.06, 15.86] | 1 study · 2987 participants | Moderate |